Challenge
IAIP is scientifically interesting but can read as obscure outside a narrow specialist window. Relevant evidence often sits across posters, abstracts, patents, and third-party pages—while company-level attribution remains weak. Investors or partners may not connect the topic to ProThera without deliberate framing.